Almirall's top-performing product in first half of 2014 is part of AstraZeneca selloff

30 July 2014

Almirall (ALM: MC), Spain's largest drugmaker, has announced total revenues of 433.4 million euros ($508.8 million) for the first half of 2014. Net sales were 403.7 million euros, up 17.4% from 343.8 million euros in the first half of 2013.

The company reported a gross profit of 281.1 million euros, an increase of 23.9%. Net income rose 8.5% to 19.1 million euros. The company's shares gained 8.8% to 11.54 euros in mornng trading.

At half year, the company is confirming its growth outlook and positive business trends, which means it is standing by the guidance provided at the beginning of the year, when it said the company expected to accelerate net sales growth between mid to high teen percentage increase against 2013.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK